Jagsonpal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Jagsonpal Pharmaceuticals has a total shareholder equity of ₹1.7B and total debt of ₹93.1M, which brings its debt-to-equity ratio to 5.5%. Its total assets and total liabilities are ₹2.1B and ₹400.0M respectively. Jagsonpal Pharmaceuticals's EBIT is ₹250.3M making its interest coverage ratio -9. It has cash and short-term investments of ₹1.1B.
Key information
5.5%
Debt to equity ratio
₹93.10m
Debt
| Interest coverage ratio | -9x |
| Cash | ₹1.12b |
| Equity | ₹1.69b |
| Total liabilities | ₹399.95m |
| Total assets | ₹2.09b |
Recent financial health updates
No updates
Recent updates
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Financial Position Analysis
Short Term Liabilities: JAGSNPHARM's short term assets (₹1.8B) exceed its short term liabilities (₹287.8M).
Long Term Liabilities: JAGSNPHARM's short term assets (₹1.8B) exceed its long term liabilities (₹112.2M).
Debt to Equity History and Analysis
Debt Level: JAGSNPHARM has more cash than its total debt.
Reducing Debt: JAGSNPHARM's debt to equity ratio has reduced from 6% to 5.5% over the past 5 years.
Debt Coverage: JAGSNPHARM's debt is well covered by operating cash flow (534.7%).
Interest Coverage: JAGSNPHARM earns more interest than it pays, so coverage of interest payments is not a concern.